ArticleEBioMedicine2017
Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Establishing age-group specific reference intervals of human salivary proteome and its preliminary application for epilepsy diagnosis.Science China. Life sciences · 2025Article
- Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients.Frontiers in immunology · 2025Article
- Article
- Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.Alzheimer's research & therapy · 2023Article
- Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors.Esophagus : official journal of the Japan Esophageal Society · 2022Article
- A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options.Science China. Life sciences · 2022Article
- Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease.Diagnostics (Basel, Switzerland) · 2022Article
- Urine proteomics identifies biomarkers for diabetic kidney disease at different stages.Clinical proteomics · 2021Article
- Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2.The FEBS journal · 2021Article
- Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals.Scientific reports · 2021Article
- Discovery of bladder cancer biomarkers in paired pre- and postoperative urine samples.Translational andrology and urology · 2021Article
- [Large-scale enrichment and identification of human urinarySe pu = Chinese journal of chromatography · 2021Article
- Urinary Proteomic Characteristics of Hyperuricemia and Their Possible Links with the Occurrence of Its Concomitant Diseases.ACS omega · 2021Article
- Label-Free Liquid Chromatography-Mass Spectrometry Proteomic Analysis of Urinary Identification in Diabetic Vascular Dementia in a Han Chinese Population.Frontiers in aging neuroscience · 2021Article
- Could urinary ACE2 protein level help identify individuals susceptible to SARS-CoV-2 infection and complication?Science China. Life sciences · 2020Article
- Urinary proteomics of Henoch-Schönlein purpura nephritis in children using liquid chromatography-tandem mass spectrometry.Clinical proteomics · 2020Article
- Urine proteome of COVID-19 patients.Urine (Amsterdam, Netherlands) · 2020Article
- Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker.Frontiers in oncology · 2020Article
- Discovery of Urinary Proteomic Signature for Differential Diagnosis of Acute Appendicitis.BioMed research international · 2020Article
- Cancer metabolomic markers in urine: evidence, techniques and recommendations.Nature reviews. Urology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urine as a true non-invasive sampling source holds great potential for biomarker discovery. While approximately 2000 proteins can be detected by mass spectrometry in urine from healthy people, the amount of these proteins vary considerably. A systematic evaluation of a large number of samples is needed to determine the range of the variations. Current biomarker studies often measure limited number of urine samples in the discovery phase, which makes it difficult to determine whether proteins differentially expressed between control and disease groups represent actual difference, or are just physiological variations among the individuals, leads to failures in the validation phase with the increased sample numbers. Here, we report a streamlined workflow with capacity of measuring 8 urine proteomes per day at the coverage of >1500 proteins. With this workflow, we evaluated variations in 497 urine proteomes from 167 healthy donors, establishing reference intervals (RIs) that covered urine protein variations. We demonstrated that RIs could be used to monitor physiological changes by detecting transient outlier proteins. Furthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer. This study provided a proof-of-principle workflow for the use of urine proteome for health monitoring and disease screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.